Thursday, June 24, 2004 :: IMAGING DIAGNOSTIC SYSTEMS IS GRANTED CHINESE PATENT
IMAGING DIAGNOSTIC SYSTEMS IS GRANTED CHINESE PATENT

FOR IMMEDIATE RELEASE

Fort Lauderdale, Florida, June 24, 2004—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that the International patent application titled “DIAGNOSTIC TOMOGRAPHIC LASER IMAGING APPARATUS” was issued May 19, as Chinese patent No. ZL95197940X; in the name of Richard J. Grable for a period of 20 years from the date of filing until July 10, 2015 and is exclusively licensed to Imaging Diagnostic Systems.

This patent protects the basic design of the CTLMÒ Computed Tomography Laser Breast Imaging System, as does the encryption of CTLMÒ software. An additional five patent applications are currently pending in China, to further protect the Company’s intellectual property.

Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast imaging system. The CTLMâ system is the first patented breast-imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography. The CTLMâ system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.

Please visit Imaging Diagnostic Systems’ website at www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.

Investor Relations: Media Relations:
Rick Lutz Margie Adelman
lcgroup@mindspring madelman@adelmancommunications.com
404-261-1196 561.347.6768

Tuesday, May 4, 2004 :: Imaging Diagnostic Systems, Inc Ships CTLM® system to Dubai
Imaging Diagnostic Systems, Inc Ships CTLM® system to Dubai

Revenue To Be Recognized in Fourth Quarter

Fort Lauderdale, Florida, May 4, 2004—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that the Company has shipped the CTLM® system to Dubai as a result of a purchase order from Axies Medical LLC of Dubai, United Arab Emirates (UAE) from February 3, 2004. Full payment was received and revenues will be booked in the company’s next 10-KSB filing. The order was originally received at the 28th Arab Health Conference held in Dubai from January 18-21, 2004.

Ed Horton COO/Imaging Diagnostic Systems commented, "We are pleased that Dubai, United Arab Emirates will be receiving its second CTLMâ system. As we place more units, we anticipate that the references from previous installations will assist us in generating additional sales." He continued, "It is also of some significance that we have now booked revenue from a number of units shipped since the beginning of this year."

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast imaging system. The CTLMâ system is the first patented breast-imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography. The CTLMâ system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations: Public Relations:
Rick Lutz Margie Adelman
404-261-1196 561-347-6768
lcgroup@mindspring.com madelman@adelmancommunications.com

Wednesday, April 28, 2004 :: IMAGING DIAGNOSTIC SYSTEMS GRANTED CANADIAN PATENT
IMAGING DIAGNOSTIC SYSTEMS GRANTED CANADIAN PATENT

Intellectual Property Portfolio Contributes To Shareholder Value

FOR IMMEDIATE RELEASE
Fort Lauderdale, Florida, April 28, 2004—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that the International patent application filed April 1999 for “LASER IMAGING APPARATUS USING BIOMEDICAL MARKERS THAT BIND TO CANCER CELLS” was granted as Canadian patent No. 2,373,299 for a period of twenty years from the date of filing until April 1, 2019.

Robert Wake, Vice President of Engineering stated, “This patent, the Canadian equivalent of US Letters Patent 5,952,664, broadly covers the optical imaging of fluorescent compounds. This will be extremely valuable in the future, as work by collaborators, such as Schering, AG and others results in developing cancer-specific fluorophores. Once these fluorophores are validated, they will greatly enhance the diagnostic value of the CTLM.”


Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast imaging system. The CTLMâ system is the first patented breast-imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography. The CTLMâ system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.

Investor Relations: Media Relations:
Rick Lutz Margie Adelman
lcgroup@mindspring madelman@adelmancommunications.com
404-261-1196 561.347.6768

Friday, April 16, 2004 :: Imaging Diagnostic Systems Announces Retirement of CEO/Chairman of the Board
Imaging Diagnostic Systems Announces Retirement of CEO/Chairman of the Board

For Immediate Release
Fort Lauderdale, Florida, April 16, 2004—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), an industry leader in the field of Medical Optical Imaging, which has developed a patented breast-imaging system that utilizes state-of-the-art laser technology and proprietary algorithms to create cross-sectional images and 3-D images of the breast for the detection of cancer, announced today that Linda B. Grable, CEO, Chairman of the Board and co-founder has retired effective April 15, 2004. The Company and its directors, officers and employees greatly appreciate her dedicated leadership, passion and service for the past 10 years and wish her well in retirement. Mrs. Grable has been Chief Executive Officer since August 2001 and, since inception in 1993, has served as Chairman of the Board of the Company.

The Board of Directors has appointed Jay S. Bendis and Sherman Lazrus as Co-Chairmen of the Board and has begun an immediate search for a new CEO. Meanwhile, the Board appointed Allan L. Schwartz, Executive Vice President and Chief Financial Officer, to serve as interim CEO until a new CEO is appointed.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast imaging system. The CTLMâ system is the first patented breast-imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography. The CTLMâ system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations: Public Relations:
Rick Lutz Margie Adelman
404-261-1196 561-347-6768
lcgroup@mindspring.com madelman@adelmancommunications.com